secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2023-07-03T23:59:59+00:00
Accession:  0001387131-23-008172
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix completes $25M acquisition of two marketed migraine products from Upsher-Smith
--------------------------------------------------------------------------------

- Paid $22M total: $12M at closing, $3M deferred, $10M for inventory; products generated ~$23M in 2022 sales.
- Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray) both FDA-approved for acute migraine.
- Transition services agreement: $100K/mo for 6 months, $150K/mo for months 7-9, plus up to $150K/mo per service category.
- Zembrace patent protection to 2036; Tosymra patent to 2031; builds commercial infrastructure for potential TNX-102 SL launch.
- Acquisition complements Tonix's TNX-1900 intranasal oxytocin program for migraine prevention.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000138713123008172/0001387131-23-008172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000138713123008172/tnxp_8k-063023.htm
  HTML page:      https://secwatch.observer/filing/0001387131-23-008172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer